Drugs
New research has shed light on the potential of bexarotene, a retinoid X receptor agonist, in the prevention of small cell lung cancer. A study conducted by researchers at the Washington University, Alvin J. Siteman Cancer Center, has revealed that bexarotene significantly reduced tumor incidence, number, and load in a
Drugs
A recent study published in the Journal of Steroid Biochemistry and Molecular Biology has identified the regulation of cell cycle and RNA transcription genes in PC-3 human prostate cancer cells treated with luteolin. The research reveals that luteolin significantly inhibits prostate cancer cells in vitro and in vivo, but the
Drugs
Recent studies published in the journal Molecular Pharmaceutics have shed new light on the potential therapeutic benefits of R-flurbiprofen in treating gastric cancer. Researchers at the Fourth Military Medical University, Department of Pharmacology, found that R-flurbiprofen was highly effective in reducing the proliferation of gastric cancer cells in vitro and
Drugs
Researchers from the University of Maryland, Marlene and Stewart Greenebaum Cancer Center, have made significant strides in understanding the adoption of costimulated autologous T cells in patients with myeloma. The study, published in Clinical Cancer Research, involved a phase I/II clinical trial with 50 patients, showcasing rapid immune recovery
Drugs
A recent report from researchers in Shantou, People's Republic of China, has shed new light on the potential growth-inhibiting effects of arsenic trioxide when combined with epigenetic therapeutic agents on leukemia cell lines. The study, published in Leukemia & Lymphoma, found that arsenic trioxide down-regulated the global DNA
Drugs
Deregulation of insulin-like growth factor-1 receptor (IGF-1R) and focal adhesion kinase (FAK) signaling pathways plays a significant role in cancer cell proliferation and metastasis. Researchers have found that a new strategy to inhibit both FAK and IGF-1R signaling pathways is effective in decreasing the growth of pancreatic cancer xenografts. This
Drugs
Researchers at St. Louis University, led by T. Kanda, have discovered that MBP-1 exhibits a significant antiproliferative effect on breast cancer cells. Their study, published in Cancer Research, found that administration of MBP-1 resulted in a substantial regression of primary and distant tumor growth in an immunocompetent mouse model. The
Drugs
Researchers at Tohoku University's Medical Department in Sendai, Japan have found that the Ndc80 complex, composed of CDCA1-KNTC2 and SPC24-SPC25 heterodimers, is significantly overexpressed in colorectal and gastric cancers. This overexpression is associated with poor prognosis in non-small cell lung cancers. The team used qRT-PCR to evaluate the
Drugs
Researchers at Washington State University have discovered that epidermal growth factor (EGF) increases lysophosphatidic acid (LPA) production in human ovarian cancer cells, a process that requires the activation of phospholipase D2 (PLD2) and involves cross-talk between EGF and LPA receptors. This study provides new insights into the molecular mechanisms underlying
Drugs
Recent research from Hamburg, Germany, has shed light on a novel mechanism of action in cancer gene therapy, which involves a heterotypic bystander effect between endothelial cells expressing the herpes simplex virus thymidine kinase (HSVtk) suicide gene and tumor cells. This phenomenon, discovered by M. Trepel and colleagues, University Medical
Pharmaceutical industry
The US Food and Drug Administration (FDA) has approved ACTEMRA, a medication designed to specifically inhibit the biological activity of interleukin-6 (IL-6), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF)
Pharmaceutical industry
Vertex Pharmaceuticals Incorporated today provided an update on key 2010 business priorities in conjunction with the 28th Annual J.P. Morgan Healthcare Conference in San Francisco. The company also discussed recent progress in its lead development programs in hepatitis C virus (HCV) infection and cystic fibrosis (CF) and outlined proof-of-concept
